EUVIMEDEUVIMED entdecken
Klinische Studie

Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects

Marlene Fonseca iD, Andreia Guimarães, Helena Gama, Luís Magalhães, Sara Carolina Henriques iD, Nuno Silva, Luis Almeida, Patrício Soares-da-Silva

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2486 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Marlene Fonseca und 7 weiteren Autor:innen. Beteiligte Einrichtung: BlueClinical Phase I, Porto, Portugal. Hauptthemen laut MEDLINE: Epoprostenol, Drug Interactions. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐day treatment with zamicastat. Since the initial dose of epoprostenol showed to be insufficiently tolerated, it was decreased to 6 ng/kg/min. Blood samples were collected to determine the metabolites of epoprostenol and concentrations of zamicastat and its metabolites. A total of 54 subjects were enrolled and data from 28 subjects were available for pharmacokinetic analysis. The epoprostenol plus zamicastat‐to‐epoprostenol geometric means ratio (GMR) and corresponding 90% confidence interval (CI) for C av,ss and area under the plasma concentration–time curve from time 0 up to 16 h at steady state (AUC 0‐16,ss ) of the metabolites of epoprostenol were within the acceptance bioequivalence range (80.00%‐125.00%). The intrasubject coefficient of variation (ISCV) was below 10% for both parameters, on both metabolites. For zamicastat AUC 0‐τ,ss , the zamicastat plus epoprostenol‐to‐zamicastat GMR and corresponding 90% CI were within the bioequivalence acceptance range, while for zamicastat C max,ss , the lower limit of the 90% CI was slightly below the acceptance range. For zamicastat metabolites, C max,ss and AUC 0‐τ,ss and the zamicastat plus epoprostenol‐to‐zamicastat GMR were below the acceptance bioequivalence range. ISCV was between 30% and 41% for C max,ss and between 21% and 41% for AUC 0‐τ,ss , for zamicastat and both metabolites. This study showed that the administration of zamicastat did not significantly modify the cardiovascular effects of epoprostenol and that the interactions between zamicastat and epoprostenol are not expected to be clinically relevant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpoprostenolDrug InteractionsHumansMaleAdultFemaleYoung AdultMiddle AgedAdministration, OralAntihypertensive AgentsArea Under CurveInfusions, IntravenousHealthy VolunteersTherapeutic Equivalency

Stichwörter der Autor:innen

dopamine β‐hydroxylasedrug interactionepoprostenolpharmacodynamicspharmacokineticstolerabilityzamicastat

Substanzen

EpoprostenolAntihypertensive Agents

Autor:innen und Institutionen

  • BlueClinical Phase I, Porto, Portugal.
  • Research and Development, Bial-Portela & Cª S.A., Coronado (S. Romao e S. Mamede), Trofa, Portugal.
  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
  • Department of Biomedicine, Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
  • MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal.

ORCID-Profile: Marlene Fonseca, Sara Carolina Henriques

Zitieren

APA

Fonseca, M., Guimarães, A., Gama, H., Magalhães, L., Henriques, S. C., Silva, N., Almeida, L., & Soares-da-Silva, P. (2024). Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2486

Vancouver

Fonseca M, Guimarães A, Gama H, Magalhães L, Henriques SC, Silva N, et al. Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2486

BibTeX
@article{Fonseca2024,
  author = {Fonseca, Marlene and Guimarães, Andreia and Gama, Helena and Magalhães, Luís and Henriques, Sara Carolina and Silva, Nuno and Almeida, Luis and Soares-da-Silva, Patrício},
  title = {Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2486}
}
Kostenlos starten →